To evaluate the expression of estrogen receptor (ER)-beta and Ki67 in prostate cancer and study their relationship.
INTRODUCTION
Prostate cancer (PCa) is the second most common malig nancy and the fifth leading cause of cancer death in men with a total of 1.09 million new PCa cases and 307,500 diseaserelated deaths in 2012 [1] . In Malaysia, PCa is the fifth most common cancer among Malaysian men [2] . The incidence of PCa increases with age, and the disease is most often diagnosed after the age of 65 years. Hence, 60% of cases are detected at a late stage (stages 3 and 4), with only
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of epithelial cells retain their capacity to proliferate [4] . Few studies have examined the variety of pattern of ER expression in prostate tumor. One previous study revealed that ERbeta expression is reduced in highergrade prostatic adenocarcinoma compared with low and intermediategrade prostatic adenocarcinoma [5] . It has also been shown that ERbeta is highly expressed in normal human prostate and that there is a progressive loss of expression in prostatic hyperplasia and to a greater extent in invasive cancer [6] . Evidence also exists of increased ER staining intensity in malignant prostate [7] . It has been postulated that ERbeta switches its role during cancer progression. In the early phases of PCa progression, ERbeta presents as a tumor suppressing agent and then becomes a tumor promoter as cancer progresses. It may also have a role in the process of prostatic hyperplasia and malignancy [8, 9] . The expression of this biomarker may thus be useful as a predictive marker in tumor staging and prognosis and may also shed new light on targeted treatment in prostate adenocarcinoma.
Ki67 is a protein found in proliferating cells. Ki67 recognizes a proliferationspecific nuclear antigen. Normal prostate cells proliferate slowly with low Ki67 expression. In prostate tumors, high Ki67 expression is associated with a higher Gleason score and more aggressive cancer [1012] . Data from previous reports (on individual markers) suggest that ERbeta is absent or downregulated in highgrade prostate adenocarcinoma and that Ki67 is highly expressed in high grade prostate adenocarcinoma. However, no studies have looked at the coexpression or relationship between ERbeta and cell proliferation within the same tumor. In the present study, we investigated the expression of ERbeta and Ki67 and the relationship with the proliferation rate in PCa of various Gleason scores.
MATERIALS AND METHODS
This study was conducted in Universiti Kebangsaan Malaysia Medical Center, Malaysia. Ethical approval was obtained from the local ethics committee (reference number FF2014146). A total of 101 paraffinembedded blocks from cases of prostate adenocarcinoma of different Gleason grades from 100 patients diagnosed from January 2011 to June 2015 were retrieved from the department archive along with their corresponding H&Estained slides. The PCa tissues were obtained from transrectal biopsy and transurethral resection of the prostate. Representative areas of prostate adenocarcinoma were marked on each H&E stained slide and the corresponding areas on paraffin blocks were cored for construction of tissue microarrays (TMAs) Mouse monoclonal antibody against Ki67 was used at a dilution of 1:100 with normal tonsil tissue as the positive control. Rabbit monoclonal antibody against ERbeta was used at a dilution of 1:300 with human ovarian serous cystadenocarcinoma as the positive control.
Immunohistochemistry staining was performed by using the protocol from EnVision TM FLEX+ (mouse, high pH; Dako, Santa Clara, CA, USA). Primary antibodies were diluted to optimal concentration using Dako REALTM Antibody Diluent (Dako). Tissue blocks were sectioned and an initial deparaffinization and pretreatment step was performed in the Dako PTLink using the EnVision TM FLEX Target Retrieval Solution (Dako), high pH, followed by cooling at room temperature for 20 minutes and rinsing under running tap water for 3 minutes. The slides were subsequently incubated with EnVision TM FLEX peroxidase blocking reagent for 5 minutes followed by the washing step. Slides were then incubated with primary antibody at room temperature followed by incubation with EnVision TM FLEX/ HRP (Dako) for 20 minutes. Sections were then incubated with 1X DABcontaining substrate working solution for 10 minutes and then counterstained with hematoxylin. Doubleimmunofluorescent staining was performed at optimal concentrations of primary and secondary antibodies. After deparaffinization and pretreatment, the slides were incubated for 45 minutes at room temperature with the primary antibody mixture, washed with TBS for 10 minutes, and incubated in the dark moist chamber with a mixture of 2 isotypespecific secondary antibodies conjugated to Alexa Fluor 594 ® (red) and Alexa Fluor 488 ® (green) for 45 minutes. The slides were then washed with TBS for 30 minutes, followed by a counterstaining step using DAPI II (Abbott Molecular Inc., Des Plaines, IL, USA). Human ovarian cystadenocarcinoma tissue was used as a positive control. Sections stained for ERbeta were scored qualitatively and those stained for Ki67 were scored quantitatively at ×40 magnification. ERbeta was interpreted as positive when the https://doi.org/10.4111/icu.2018.59. 4 .232 cells showed nuclear immunoreactivity in 10% or more of the tumor cells (Fig. 1) . Negative staining was interpreted if no staining was seen or when less than 10% of tumor cells showed positive expression regardless of staining intensity. Results for Ki67 were interpreted as negative if there was a lack of nuclear immunoreactivity (no staining at all), low in cases with positive nuclear staining of less than 10% (Fig. 2 ) of the cells, and high in cases with positive nuclear staining of 10% or more of the cells (Fig. 3) .
For 
RESULTS
A total of 53 of 101 cases (52.5%) were positive for ER beta expression at variable levels of intensity. ERbeta was observed in 7 of 23 cases (30.4%) from group 1, 5 of 13 cases (38.5%) from group 2, 4 of 10 cases (40.0%) from group 3, 6 of 13 cases (46.2%) from group 4, and 31 of 42 cases (73.8%) from group 5 ( Table 1 ). Fig. 4 shows the number of positive cases according to prognostic group. Statistical analysis with the Pearson chisquare test showed a correlation or association between ERbeta expression and high prognostic group in which a high percentage of ERbeta positivity was found in the high prognostic group (p=0.007; Table 1) .
Of 101 cases, 98 cases (97.0%) were positive for Ki67 and 3 cases (3.0%) were negative for Ki67. As shown in Table  2 , among the proliferating cells, 50 of 98 cases showed a low Ki67 proliferation rate (less than 10%) and 48 of 98 cases showed a high Ki67 proliferation rate (10% or more). The Ki67 proliferation rate was evaluated and correlated with prognostic Gleason group as shown in Table 2 . A high Ki67 proliferation rate was seen in the higher prognostic groups (groups 4 and 5), whereas a low Ki67 proliferation rate or negative staining was found in the lower prognostic group (Fig. 5) . This was statistically significant (p<0.001, Fisher's exact test; Table 2 ). The correlation between the Ki67 proliferation rate and ERbeta expression showed that 77.1% of cases with a high Ki67 rate were positive for ER beta expression, whereas 68.0% of cases with a low Ki67 proliferation rate and 100% of cases with negative Ki67 proliferation were negative for ERbeta expression (Table  3) . Statistical analysis using Fisher's exact test showed a significant correlation between ERbeta expression and a high proliferation rate (p<0.001).
A total of 20 cases from various prognostic groups were evaluated by doubleimmunofluorescent staining for ERbeta and Ki67. Among the cases evaluated, 14 of 20 cases showed positive coexpression of ERbeta and Ki67 within the same tumor (Fig. 6) . In a few cases that coexpressed both markers, some of the proliferating cells were, however, negative for ERbeta (Fig. 2) . In 6 of 20 cases, the tumor cells did not co express ERbeta and Ki67, showing that the two markers are mutually exclusive (Fig. 6 ).
DISCUSSION
We found that ERbeta was mainly expressed in cases with a high Gleason score (scores of 9 and above). Our findings showed a gradual increment in the number of positive cases with a Gleason score of 4 to 8 and an exponen tial increase in positivity for cases with Gleason scores of 9 and 10. This is in contrast with the findings of Asgari and Morakabati [5] in which there was reduced expression of ERbeta in highergrade prostatic adenocarcinoma compared with low and intermediategrade cancer. We have no obvious explanation for the inverse expression of ERbeta and Gleason score, but we can postulate that inadequate antibody specificity, ineffective antigenbearing tissue retrieval, or the presence of unknown isoforms of ER protein may have affected the quality of immunohistochemistry [5] .
Besides, it was previously described that ERbeta, as detected by PPG5/10 antibody, may have a role in the process of de differentiation of prostate adenocarcinoma, with a higher level present in less differentiated tumor [13] . Our findings support the potential of ERbeta as a cancerpromoting agent as proposed by Christoforou et al. [8] in 2014.
It was previously shown that the expression of ERbeta is more intense in PCa than in benign prostatic hyperplasia [14] . Although we did not compare the staining intensity between benign and malignant prostate tissue, our own observation showed that the intensity of ERbeta staining is not restricted to the Gleason score.
The proliferation rate was high in cases with a Gleason score of 8 and above. Among those with positive Ki67 staining, the cases in prognostic groups 4 and 5 (Gleason scores of 8, 9, and 10) showed a higher percentage of proliferation rate than did the lower prognostic Gleason group. These findings agree with previous studies by Cowen et al. [11] and Sulik et al. [12] that reported that Ki67 levels were significantly higher in tumors with a high Gleason score. A study by Fixemer et al. [15] concluded that ER beta is expressed in the secretory epithelium of the prostate and possibly reflects androgendependent cancer cells and might have a chemopreventive effect. However, our study focused on prostate adenocarcinoma alone, not normal and premalignant tissue.
The correlation between the Ki67 proliferation rate and ERbeta expression showed that those cases with high Ki67 proliferation were positive for ERbeta expression and those cases that were negative for Ki67 were negative for ER beta expression. These findings indicate that proliferating prostate adenocarcinoma cells are expressing ERbeta. This observation was confirmed with doubleimmunofluorescent staining in which the majority of cases (14/20) showed co expression of the markers at the individual cell level. However, in a smaller number of cases, coexpression was lacking, showing that ERbeta is expressed in individual cells independent of the proliferation marker. Whether the latter group (ERbeta positive, Ki67 negative) had a better prognosis remains to be determined.
Limitations
The use of a control group is important to avoid observational bias during the interpretation of data. However, f inancial constraints were the main culprit leading to the exclusion of a control group in this study. In the future, we will try to improve on this issue with a subsequent study or a continuation of this study. 
